An international phase IIb trial of OPT-302 combination therapy for wet-AMD showed the treatment had superior results to intensive anti-VEGF-A therapy.
Melbourne-based biotech company Opthea reported the multicentre, randomised, double-masked clinical trial of 366 patients resulted in a higher mean visual acuity gain at 24 weeks compared to Lucentis monotherapy.
“In testing for superiority against very intensive anti-VEGF-A therapy, the bar was set high. Despite this, OPT-302 (2mg) combination therapy showed statistical superiority for the most accepted and sensitive primary efficacy outcome - mean visual acuity,” said study lead Professor Tim Jackson from King’s College London.
“These results indicate that combined suppression of VEGF A, C and D has considerable potential as a novel treatment for wet-AMD. OPT-302 may emerge as a combination treatment that can offer better vision gains than standard of care. Further registrational trials are clearly justified.”
